Lisa Kirby

Lisa Kirby

Auto-generated profile, based on publicly available information

Lisa Kirby

Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham , Nottingham

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2020 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
GOGrace Obeid
Grace Obeid
GDGiao Do
Giao Do
LKLisa Kirby
Lisa Kirby
CHCarolyn Hughes
Carolyn Hughes
ESEmilie Sbidian
Emilie Sbidian
LCLaurence Le Cleach
Laurence Le Cleach

15 June 2021 in Skin Health and Disease
Verified
Journal Article
Open access
PDF file
FTF. Tasker
F. Tasker
LKL. Kirby
L. Kirby
DGD. J. C. Grindlay
D. J. C. Grindlay
FLFiona Lewis
Fiona Lewis
RSR. C. Simpson
R. C. Simpson
Background: Lichen sclerosus (LS) is a chronic, inflammatory dermatosis. Initial treatment with superpotent topical corticosteroids is the accepted and evidence-based first-line therapy. For those who do not respond after exclusion of other potentiating factors, the best second-line therapy is unclear. Laser therapy is an emerging treatment for genital LS and despite uncertain efficacy its use is gaining popularity in the private sector. Objectives: We aimed to review the effectiveness of laser therapy for genital LS in men, women and children. Methods: We conducted a systematic review of all primary studies reporting the use of laser in genital LS. Ovid MEDLINE, PubMed, Ovid Embase, Cochrane CENTRAL, Web of Science, CINAHL and PsycINFO were searched from inception to February 2021. The quality of the studies was assessed using the revised Cochrane risk-of-bias tool for randomized trials, ROBINS-I tool for non-randomized trials and Joanna Briggs Institute checklist for case studies. Results: A total of 24 studies, involving 616 adults, met inclusion criteria. These were six randomized controlled trials (RCTs), one non-randomized trial, nine single arm trials and eight case series. Where assessed, most studies suggest that laser therapy in patients with LS may improve symptoms, clinical signs, quality of life and sexual function. However, results were highly heterogeneous and methodological quality was very low, therefore meta-analysis was not possible. Conclusions: There is poor evidence to support the use of laser therapy for genital LS at present. Effectiveness of laser needs to be robustly investigated in well-conducted RCTs.

15 June 2021 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
LKL. Kirby
L. Kirby
SGS. Gran
S. Gran
FOF. Orekoya
F. Orekoya
COC. Owen
C. Owen
RSR. Simpson
R. Simpson
Increasing evidence suggests the pathogenesis of male genital lichen sclerosus (LS) is driven by chronic, occluded exposure of susceptible epithelium to the irritant effect of urine (1, 2). It is not clear how this can be extrapolated to females, however, the typical ‘figure of eight’ distribution seen in female genital LS suggests that urine could be implicated. This has not yet been robustly investigated.

22 September 2020 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
GOG. Obeid
G. Obeid
GDG. Do
G. Do
LKL. Kirby
L. Kirby
CHC. Hughes
C. Hughes
ESE. Sbidian
E. Sbidian
LCL. Le Cleach
L. Le Cleach

12 February 2021 in Skin Health and Disease
Verified
Journal Article
Open access
PDF file
LKL. Kirby
L. Kirby
SGS. Gran
S. Gran
IKI. Kreuser-Genis
I. Kreuser-Genis
COC. Owen
C. Owen
RSR. Simpson
R. Simpson
Background Lichen sclerosus (LS) is a scarring chronic inflammatory disease with a predilection for genital skin in both sexes. The aetiology of LS is controversial, but evidence increasingly suggests that the occluded exposure of susceptible epithelium to urine is involved in the pathogenesis of genital LS in males. This theory has not yet been robustly investigated in females. Objectives This review and meta‐analysis examined whether there is an association between urinary incontinence (UI) and genital lichen LS in females. Methods We performed a comprehensive search of MEDLINE, Embase and CINAHL to identify observational studies assessing the prevalence of UI in females with LS. DerSimonian and Laird random‐effects models were used to estimate the overall pooled prevalence and risk ratio compared to controls. Heterogeneity was assessed. Results In total, eight studies met the inclusion criteria and five studies were included in a meta‐analysis. Three studies were graded as moderate quality and five were poor. The pooled prevalence for UI in LS was 0.35 (95% confidence interval [CI] 0.13–0.58, I2 = 98.4%). The risk ratio of UI in LS was 0.97 (95% CI 0.53–1.75, I2 = 87.5%). Conclusion There appears to be no difference between patients with LS and those without LS in terms of UI. Studies are limited by clinical and methodological quality and heterogeneity is high. Well‐designed prospective studies are needed.

21 February 2019 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
SRS. Rees
S. Rees
LKL. Kirby
L. Kirby
RSR.C. Simpson
R.C. Simpson